Research programme: encapsulated cell therapy - Semma Therapeutics

Drug Profile

Research programme: encapsulated cell therapy - Semma Therapeutics

Alternative Names: Stem cell-derived beta cells - Semma Therapeutics

Latest Information Update: 21 Apr 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Semma Therapeutics
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Pancreatic beta cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Type 1 diabetes mellitus

Most Recent Events

  • 24 Mar 2015 Semma Therapeutics enters into an undisclosed agreement with Novartis Pharmaceuticals
  • 24 Mar 2015 Semma Therapeutics in-licenses stem cell-derived beta cells technology from Harvard Stem Cell Institute for Type-1 diabetes mellitus
  • 09 Oct 2014 Preclinical trials in Type-1 diabetes mellitus in USA (unspecified route) (Semma Therapeutics website, April 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top